Koichi Yoneyama1, Rina Shibata2, Akira Igarashi3, Shigeyuki Kojima3, Yoshiko Kodani3, Kinya Nagata3, Keisuku Kurose1, Rieko Kawase1, Toshiyuki Takeshita1, Seisuke Hattori4. 1. Department of Obstetrics and Gynecology, Nippon Medical School Hospital, Tokyo, Japan. 2. Division of Cellular Proteomics, Institute of Medical Science, The University of Tokyo, Tokyo, Japan. 3. Department of Advanced Medicine and Development, BML Inc., Saitama, Japan. 4. Division of Cellular Proteomics, Institute of Medical Science, The University of Tokyo, Tokyo, Japan Division of Biochemistry, School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan hattoris@pharm.kitasato-u.ac.jp.
Abstract
BACKGROUND/AIM: Accumulating evidence shows that various types of cancers induce a specific immune response, resulting in the production of antibodies against self-components (autoantibodies). The aim of the present study was to identify antigens for autoantibodies in sera from endometrial cancer patients as novel diagnostic markers for the disease. MATERIALS AND METHODS: The reactivity of individual sera from patients was examined by 2-dimensional (2-D) immunoblotting using HeLa cell lysates as antigens to identify autoantigens. ELISA was established to quantitatively measure autoantibody titer of patients' sera. RESULTS: A mitochondrial protein, dihydrolipoamide dehydrogenase (DLD), was identified as an autoantigen specific to endometrial cancer patients. The levels of immunoglobulin (Ig)A but not IgG autoantibody to DLD were significantly increased in the sera of endometrial cancer patients. CONCLUSION: IgA autoantibody against DLD could be a novel diagnostic marker for endometrial cancer. Copyright
BACKGROUND/AIM: Accumulating evidence shows that various types of cancers induce a specific immune response, resulting in the production of antibodies against self-components (autoantibodies). The aim of the present study was to identify antigens for autoantibodies in sera from endometrial cancerpatients as novel diagnostic markers for the disease. MATERIALS AND METHODS: The reactivity of individual sera from patients was examined by 2-dimensional (2-D) immunoblotting using HeLa cell lysates as antigens to identify autoantigens. ELISA was established to quantitatively measure autoantibody titer of patients' sera. RESULTS: A mitochondrial protein, dihydrolipoamide dehydrogenase (DLD), was identified as an autoantigen specific to endometrial cancerpatients. The levels of immunoglobulin (Ig)A but not IgG autoantibody to DLD were significantly increased in the sera of endometrial cancerpatients. CONCLUSION: IgA autoantibody against DLD could be a novel diagnostic marker for endometrial cancer. Copyright
Authors: I F Duarte; J Caio; M F Moedas; L A Rodrigues; A P Leandro; I A Rivera; M F B Silva Journal: Cell Mol Life Sci Date: 2021-10-31 Impact factor: 9.261